TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02882880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Luco Hybrid OSA Appliance
Description: Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).

Intervention type: DEVICE
Group type: OTHER
Intervention: The Luco Hybrid OSA Appliance
Description: Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
Study: NCT01097070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevirimat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevirimat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevirimat
Study: NCT03180515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S Neurostimulator
Description: Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
Study: NCT04317924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid felt
Description: Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care after air leak post lung resection
Study: NCT03437876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal microbiota transplant
Description: All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
Study: NCT01851187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal psychological intervention
Description: emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine prenatal care
Description: Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine prenatal care
Description: Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
Study: NCT00953342

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard medical care
Study: NCT03988478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detoxification & psychotherapeutic support
Study: NCT02611375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral nerve somatosensory stimulation
Description: Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
Study: NCT03558464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads
Study: NCT00445263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIROFIBAN
Description: intravenous infusion
Study: NCT00922441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg group
Description: Fimasartan 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg group
Description: Fimasartan 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference (Valsartan 80 mg) group
Description: Reference (Valsartan 80 mg)
Study: NCT03386617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA
Description: Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded.
Study: NCT02690415

Intervention type: PROCEDURE
Intervention: Antibiotics Given
Description: Patients who's treating physician prescribed antibiotics

Intervention type: PROCEDURE
Intervention: Antibiotics Given
Description: Patients who's treating physician prescribed antibiotics

Intervention type: PROCEDURE
Intervention: Antibiotics not given
Description: Patients who's treating physician did not prescribed antibiotics

Intervention type: PROCEDURE
Intervention: Antibiotics not given
Description: Patients who's treating physician did not prescribed antibiotics
Study: NCT02617433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
Study: NCT01115283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual learning
Description: Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Games
Description: Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occlusion therapy
Description: Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
Study: NCT04068285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will be making aerobic exercise
Study: NCT03081143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 on day 1, 8, 15
Study: NCT05992961

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin I
Description: Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists.
Study: NCT00445263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CORONAROGRAPHY
Description: standard procedure of coronarography
Study: NCT02212548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG Hydrogel (SpaceOAR)
Description: A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
Study: NCT01528943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostacycline
Description: Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: same volume as the group that are allocated to prostacycline
Study: NCT03978013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Pomegranate juice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Apple juice
Study: NCT03860116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP-based case management service
Description: The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard-of-care followup service
Description: When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care followup service
Description: When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
Study: NCT03795025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training 3x10RM + no training
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training 6x10RM + no training
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3x10RM + 6x10RM
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
Study: NCT02679989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
Study: NCT00100841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT00629876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen.
Study: NCT03449992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink
Study: NCT02865603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game
Description: PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
Study: NCT02559726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography (TEE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography (TEE)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography (TEE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) with gadolinium enhancement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) with gadolinium enhancement

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI) without gadolinium enhancement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D electrocardiographic mapping (ECM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D electrocardiographic mapping (ECM)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D electrocardiographic mapping (ECM)
Study: NCT03851146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LeY CAR T cells
Description: Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
Study: NCT02268747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction.
Study: NCT01463267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone or pillbox
Description: People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone or pillbox
Description: People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-reminding
Description: As a comparison, the devices will collect medication taking information without providing reminders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-reminding
Description: As a comparison, the devices will collect medication taking information without providing reminders.
Study: NCT04120454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT00055861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01901861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg is given before meal ingestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given before meal ingestion
Study: NCT03058367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (330mg)
Description: High dose capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (165mg)
Description: Low dose capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to verum capsules
Study: NCT00693602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Chemotherapy
Study: NCT02570139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConvaTec Sensi-Care Protective Barrier
Description: Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
Study: NCT00445263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CORONAROGRAPHY
Description: standard procedure of coronarography
Study: NCT04408027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-Care Cognitive Behavioural Therapy
Description: The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
Study: NCT02869113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98751 (Y65-110)
Description: 10 µL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98751 (Y65-102)
Description: 10 µL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98751 (Y65-106)
Description: 10 µL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (Control)
Description: 10 µL in other eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (Control)
Description: 10 µL in other eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (Control)
Description: 10 µL in other eye
Study: NCT02582164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Biomedical Engineering's Long-working distance OCT
Description: The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Biomedical Engineering's Long-working distance OCT
Description: The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Biomedical Engineering's Long-working distance OCT
Description: The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.